title: Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers.
abstract: We examined the subcellular localization of BRCA1 proteins using immunohistochemical staining with C-terminal (GLK-2 antibody) and N-terminal (Ab-2 antibody) monoclonal antibodies in 44 familial ovarian cancers. Among these, 24 cases were associated with 13 independent germ-line mutations of BRCA1, and loss of heterozygosity (LOH) at one or more BRCA1 microsatellite markers was found in all 21 informative tumors tested. With GLK-2 antibody, cytoplasmic staining was observed in 15 of 16 tumors (93.8%) with mutation in exon 11, and BRCA1 staining was absent in 8 of 8 tumors (100%) with mutation in exons other than exon 11. When immunohistochemical staining was performed with Ab-2 antibody, both nuclear and cytoplasmic staining were observed in 14 of 16 tumors (87.5%) with mutation in exon 11. Interestingly, nuclear staining was observed in 3 of 3 tumors (100%) with mutation downstream of exon 11, even though no staining was detected in 5 of 5 tumors (100%) with mutation upstream of exon 11. On the other hand, in familial ovarian cancers without BRCA1 mutations, nuclear staining or both nuclear and cytoplasmic staining was observed in 18 of 20 specimens (90%) and 20 of 20 specimens (100%) with GLK-2 antibody and with Ab-2 antibody, respectively. These results suggest that an immunohistochemical assay in combination with employing the C-terminal and the N-terminal antibodies appears to have potential as a reliable and useful technique for the screening of BRCA1 mutations, at least to predict the status of mutation, upstream or downstream of exon 11.
authors.affiliation: Department of Obstetrics and Gynecology, Niigata University School of Medicine, Niigata 951-8510, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kashima
authors.forename: T
authors.initials: T
authors.lastname: Oite
authors.forename: Y
authors.initials: Y
authors.lastname: Aoki
authors.forename: K
authors.initials: K
authors.lastname: Takakuwa
authors.forename: H
authors.initials: H
authors.lastname: Aida
authors.forename: H
authors.initials: H
authors.lastname: Nagata
authors.forename: M
authors.initials: M
authors.lastname: Sekine
authors.forename: H J
authors.initials: HJ
authors.lastname: Wu
authors.forename: Y
authors.initials: Y
authors.lastname: Hirai
authors.forename: Y
authors.initials: Y
authors.lastname: Wada
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Hasegawa
authors.forename: T
authors.initials: T
authors.lastname: Sonoda
authors.forename: T
authors.initials: T
authors.lastname: Maruo
authors.forename: I
authors.initials: I
authors.lastname: Nagata
authors.forename: M
authors.initials: M
authors.lastname: Ohno
authors.forename: M
authors.initials: M
authors.lastname: Suzuki
authors.forename: I
authors.initials: I
authors.lastname: Kobayashi
authors.forename: K
authors.initials: K
authors.lastname: Kuzuya
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Torii
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
mesh_terms: D019313:BRCA1 Protein / Q000032:analysis*; D005260:Female; D019398:Genes, BRCA1; D018095:Germ-Line Mutation; D006801:Humans; D007150:Immunohistochemistry; D019656:Loss of Heterozygosity; D010051:Ovarian Neoplasms / Q000737:chemistry / Q000235:genetics*; D010053:Ovary / Q000737:chemistry
chemical_list: D019313:BRCA1 Protein